NYSE: CRL · Life Sciences Tools & Services
Charles River Laboratories
Charles River is a contract research organization serving drug developers. It has three segments: Research Models and Services (purpose-bred rodents and other research models), Discovery and Safety Assessment (outsourced discovery and the non-clinical safety testing regulators require) and Manufacturing Solutions (microbial testing and biologics testing). 2025 revenue was $4.02 billion (−0.9%). Goodwill and intangible impairments produced a net loss of $144 million. Birgit Girshick became CEO in May 2026. The company has sold its CDMO and Cell Solutions businesses and some European discovery sites.
Last updated
Analysis last edited: October 14, 2026 · Financial data fetched: October 17, 2026 10:07 (SEC EDGAR) · Source 10-K filed: February 18, 2026
Built on10-K FY2025 · filed 2026-02-1810-Q (quarter ended 2026-09-26) · filed 2026-11-04
Next update expectedAfter FY2026’s 10-K is filed (roughly 60–90 days after fiscal year end (sooner for larger filers)), financials and analysis will be refreshed.
01
At a glanceFrom SEC data
Eight headline measures, each placed among the companies covered on this site.
- Revenue growthCAGRSmooths out year-to-year swings into "grew X% a year on average." Makes growth pace comparable across companies of very different sizes.
- 6.5%
- Operating marginOperating marginHow many cents of operating profit are left per dollar of revenue. Reflects pricing power and cost structure.
- 0.6%
- ROIC minus WACCROIC − WACC spreadThe difference between ROIC and WACC. Consistently positive implies value creation; consistently negative implies value destruction.
- -8.3 pts
- Net debt ÷ EBITDAEBITDAOperating income with D&A added back. A rough proxy for cash-generating power that’s less distorted by capital intensity, depreciation method, or financing/tax differences than net income.
- 4.5x
- Cash conversionOperating CF ÷ net income (cash conversion)How much of reported profit shows up as actual cash. 1x or higher means profit is backed by cash.
- —
- Dividend raisesDividend per shareTotal annual dividend paid per share (sum of all declared payments for the year).
- —
- P/E todayP/EShare price ÷ EPS — how many years of current earnings the stock price represents. This site uses the period-end figure as reported in the filing.
- 416.4x
- Betaβ (beta)How much a stock moves, on average, for a 1% move in the overall market. Above 1 means more volatile than the market, which raises the return shareholders require. This site computes it from about 2.5 years (roughly 130 weeks) of weekly returns, built from Yahoo Finance daily prices, regressed against an S&P 500 ETF (SPY) as the market proxy, then applies the well-known long-run mean-reversion adjustment (0.67 × β + 0.33) as the WACC default.
- 0.85
Higher than 37% of 372 non-financial companies
Average yearly growth over the years shown
Higher than 5% of 311 non-financial companies
Latest fiscal year (FY2025)
Higher than 7% of 311 non-financial companies
Return on capital above (or below) its estimated cost
Higher than 84% of 304 non-financial companies
Below 0 means more cash than debt
Operating cash flow ÷ net income
Years the dividend per share rose, of the last 5
Latest close 2026-11-04; trailing 12 months to 2026-09-26
Above 1 = moves more than the market
Each marker shows where this company sits among the non-financial companies covered on this site, not all listed companies (left = lowest, right = highest). A high position is not automatically good — for net debt ÷ EBITDA, higher means more debt. Details and formulas are in the sections below and in How to read this.
02
Valuation todayFrom SEC data
Price-based measures at the latest close, next to the same measures at the last fiscal year-end.
Share price$340.01close on 2026-11-04
Market cap$16.73B
- P/EP/EShare price ÷ EPS — how many years of current earnings the stock price represents. This site uses the period-end figure as reported in the filing. today
- 416.4x
- P/BP/BShare price ÷ book value per share. Below 1x means the market values the company below its accounting net worth. This site uses the closing price nearest the fiscal year-end and highlights sub-1x readings. today
- 5.3x
- EV/EBITDAEV/EBITDAEnterprise value (≈ market cap + interest-bearing debt − cash) as a multiple of EBITDA — roughly, "how many years of EBITDA to buy the whole company." Lower is generally viewed as cheaper, and it’s more comparable than P/E across companies with different debt loads or depreciation policies. This site excludes noncontrolling interests from the EV calculation. today
- 43.5x
- FCF yieldFree cash flow (FCF)Operating CF minus capital expenditures — cash generated by the business after funding its own investment, available for dividends, buybacks, acquisitions, or debt paydown. Acquisitions and securities purchases (also in investing CF) are not subtracted, so FCF can be positive in a year when total investing CF exceeds operating CF. today
- 3.1%
- Dividend yieldDividend per shareTotal annual dividend paid per share (sum of all declared payments for the year). today
- —
At FY2025 year-end: —
Earnings: trailing 12 months to 2026-09-26
At FY2025 year-end: 3.2x
Book value at FY2025 year-end
At FY2025 year-end: 27.9x
EBITDA for FY2025
At FY2025 year-end: 5.2%
Free cash flow for FY2025
Dividends per share for FY2025
“Today” uses the latest closing price (2026-11-04, Yahoo Finance daily closing prices) and shares outstanding at the last fiscal year-end. The rest of this page — including the financial table and ROIC vs. WACC — uses fiscal year-end prices. These are reference figures, not a judgment of whether the stock is cheap or expensive.
03
What changed since last earningsFrom SEC data
The latest reported quarter against the same quarter a year earlier, the balance sheet against the previous quarter-end, and what management said in its latest earnings release.
Quarter ended Sep 26, 2026.
- Revenue$1B → $983M (vs. a year earlier)↓ −2.2%$1B → $983M (vs. a year earlier)
- Operating margin13.3% → 20.6% (vs. a year earlier)↑ +7.3 pts13.3% → 20.6% (vs. a year earlier)
- Net income$54M → $333M (vs. a year earlier)↑ +512.0%$54M → $333M (vs. a year earlier)
- Diluted EPS$1.10 → $6.86 (vs. a year earlier)↑ +523.6%$1.10 → $6.86 (vs. a year earlier)
- Cash$192M → $200M (vs. previous quarter-end)↑ +4.4%$192M → $200M (vs. previous quarter-end)
Source: Form 10-Q ↗ (SEC XBRL). Long-term debt is the tagged long-term debt figure and leaves out short-term borrowings.
From the earnings release of Nov 4, 2026.
Management outlook ↑ Raised
Raised organic revenue guidance by 100 basis points and non-GAAP EPS guidance by $0.15 at the midpoint. Source sentence
Organic revenue guidance increasing by 100 basis points and non-GAAP earnings per share guidance increasing by $0.15 at midpoint.
Key changes
Q3 revenue $982.7M, down 2.2%. Source sentence
Revenue was $982.7 million, a decrease of 2.2% from $1,004.9 million in the third quarter of 2025, primarily driven by the impact of the May 2026 divestitures.
Organic revenue up 4.7%. Source sentence
On an organic basis, revenue increased 4.7%, driven by revenue growth in the Manufacturing Solutions (Manufacturing) and Discovery and Safety Assessment (DSA) segments.
Written by AI. A line appears only if its figures and direction match the quoted sentence, which an automatic check confirms. Companies' outlooks are their own and may not be met. Read the release ↗
04
Company profileFrom SEC dataShow
- Legal name
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- Headquarters
- WILMINGTON, MA
- Fiscal year end
- 12/27
- Exchange & ticker
- NYSE: CRL
- Industry
- Life Sciences Tools & Services
- CIK
- 1100682
- Website
- https://www.criver.com/ ↗
- IR page
- https://ir.criver.com/ ↗
Workforce (as of FY2025 year-end)
Employees
19,700
Source: Form 10-K (FY2025) cover page and business description
05
Earnings calendarFrom SEC dataShow
When the company reports each quarter: the quarter-end date, the day results were released, and when the 10-Q or 10-K was filed.
Next report
Q4 FY2026
Quarter end: December 2026. In past years, Q4 results were released 46–53 days after quarter end (Feb 18, 2026; Feb 19, 2025; Feb 14, 2024). No date has been announced in the sources this site uses.
Reporting pattern
- Fiscal year ends around December 27.
- Reports four times a year: three quarterly reports (10-Q) and an annual report (10-K) for Q4.
- Earnings releases came 39–53 days after quarter end over the last 12 quarters.
| Quarter | Quarter ended | Earnings release (8-K) | Report filed (10-Q / 10-K) |
|---|---|---|---|
| Q3 FY2026 | Sep 26, 2026 | Nov 4, 2026 (+39 days) | Nov 4, 2026 10-Q (+39 days) |
| Q2 FY2026 | Jun 27, 2026 | Aug 5, 2026 (+39 days) | Aug 5, 2026 10-Q (+39 days) |
| Q1 FY2026 | Mar 28, 2026 | May 7, 2026 (+40 days) | May 7, 2026 10-Q (+40 days) |
| Q4 FY2025 | Dec 27, 2025 | Feb 18, 2026 (+53 days) | Feb 18, 2026 10-K (+53 days) |
| Q3 FY2025 | Sep 27, 2025 | Nov 5, 2025 (+39 days) | Nov 5, 2025 10-Q (+39 days) |
| Q2 FY2025 | Jun 28, 2025 | Aug 6, 2025 (+39 days) | Aug 6, 2025 10-Q (+39 days) |
| Q1 FY2025 | Mar 29, 2025 | May 7, 2025 (+39 days) | May 7, 2025 10-Q (+39 days) |
| Q4 FY2024 | Dec 28, 2024 | Feb 19, 2025 (+53 days) | Feb 19, 2025 10-K (+53 days) |
| Q3 FY2024 | Sep 28, 2024 | Nov 6, 2024 (+39 days) | Nov 6, 2024 10-Q (+39 days) |
| Q2 FY2024 | Jun 29, 2024 | Aug 7, 2024 (+39 days) | Aug 7, 2024 10-Q (+39 days) |
| Q1 FY2024 | Mar 30, 2024 | May 9, 2024 (+40 days) | May 9, 2024 10-Q (+40 days) |
| Q4 FY2023 | Dec 30, 2023 | Feb 14, 2024 (+46 days) | Feb 14, 2024 10-K (+46 days) |
Source: SEC EDGAR filing history. Release dates are the dates the earnings release was furnished to the SEC on Form 8-K (Item 2.02), which is normally the day results are announced. For a quarter whose 10-Q or 10-K isn’t filed yet, the date is the latest Item 2.02 8-K since the previous report, which may be a preliminary or other results-related update. Fiscal years are labeled by the calendar year in which they end.
06
Flagship products & servicesSite analysis
RMS
Research models
Examples: Over 140 stocks and strains of purpose-bred rodents
Also large research models and Insourcing Solutions.
DSA
Safety assessment and discovery
Examples: Toxicology, bioanalysis, in vitro testing
Non-clinical studies required by regulators.
Manufacturing
Microbial Solutions
Examples: Endosafe
Rapid quality-control testing, including lot-release testing for injectables.
Descriptions are from the FY2025 Form 10-K.
U.S., worldwide and country/regional share of flagship products/services
Only shares the company itself states (in its filings or press releases, sometimes citing a research firm) are shown. Scope and timing vary by figure — treat these as approximate.
Outsourced drug discovery, non-clinical development and safety testing
Worldwide
U.S. share
—
Not disclosedWorldwide share
Largest provider
Company-disclosedPer the 10-K; no percentage is given.
Sources:
07
Recent strategic focusSite analysis
2025–2026 changes.
CEO transition
James Foster stepped down as CEO and Chairman, and COO Birgit Girshick became CEO on May 5, 2026. Glenn Coleman joined as CFO.
Source: 8-Ks filed 2026-01-09 and 2026-02-18
Divestitures
In May 2026 Charles River completed the divestitures of its CDMO and Cell Solutions businesses and certain European Discovery Services sites.
Source: Q2 2026 press release
SEC inquiry closed
On November 14, 2025, the SEC Division of Enforcement said it concluded its NHP-sourcing investigation and does not intend to recommend enforcement action.
Source: 8-K filed 2025-11-17
Investor Day
In September 2026 the company outlined its Pathway to Purpose strategy and long-term targets through 2030, and reaffirmed 2026 guidance at the upper ends of the prior ranges.
Source: Press release, 2026-09-24
Capex ÷ D&A (FY2025)
0.54x
Below depreciation — investment is being pared back
formulacapital expenditures ÷ depreciation & amortization
e.g.$219M ÷ $403M = 0.54x
termsCapital expenditures (capex) · Depreciation & amortization (D&A)
M&A spend (6-year total)
$2.2B
Latest year: $0
Cash-flow-statement spending on acquisitions, net of cash acquired
Where the money goes, over time
Unit: $M. Capex went from $167M in FY2020 to $219M in FY2025
- Capex
- M&A spend
formulacapital expenditures ÷ depreciation & amortization
termsCapital expenditures (capex) · Depreciation & amortization (D&A)
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-18
08
Key figures at a glanceFrom SEC data
FY2020–FY2025, 6 years.
Revenue (FY2025)
$4.02B
As reported in the 10-K
Revenue CAGR (5 years)
+6.5%▲favorable
formula(last-period revenue ÷ first-period revenue) ^ (1 ÷ years) − 1
e.g.($4,015M ÷ $2,924M) ^ (1÷5) − 1 = 6.5%
termsCAGR · ^ (exponent) · Revenue (net sales)
Operating margin (FY2025)
0.6%▼caution
-14.2pt vs. 5 years ago
formulaoperating income ÷ revenue × 100
e.g.$25M ÷ $4,015M × 100 = 0.6%
ROE (FY2025)
-4.4%▼caution
6-year average: 10.4%
As reported in the 10-K
P/B (FY2025 end)
3.17x
formulafiscal year-end closing price ÷ book value per share
e.g.$203.66 ÷ $64.30 = 3.17x
Period-end (fiscal year-end) value, not today's P/B
EV/EBITDA (FY2025 end)
27.9x
formula(market cap + interest-bearing debt − cash and equivalents) ÷ (operating income + depreciation & amortization)
e.g.($10,024M + $2,136M − $214M) ÷ ($25M + $403M) = 27.9x
termsEV/EBITDA · Market capitalization · Interest-bearing debt · EBITDA · Depreciation & amortization (D&A)
Period-end (fiscal year-end) value, not today's multiple
- ▲
Revenue grew +6.5% a year over 5 years (strong growth)
From $2.92B in FY2020 to $4.02B in FY2025. The annualized rate (CAGR) makes it possible to compare growth pace across companies of different sizes.
- ▼
Operating margin declined: 14.8% → 0.6%
How much operating profit is left per $100 of revenue. It moved -14.2 points over 5 years — pricing power, cost control, and product mix all show up here.
- ―
Equity ratio is 44.4% (a middling level)
The share of total assets funded by equity rather than debt. 50%+ is often read as low bankruptcy risk, though the right level varies by industry (real estate and leasing run lower, for instance).
- ▲
Free cash flow was positive in 6 of 6 years
Operating cash flow minus capital expenditures: the cash left over after funding the business’s own investment, available for dividends, buybacks, acquisitions, or debt paydown. A negative year can mean heavy investment, or weak core earnings — worth distinguishing.
- ▲
ROE averaged 10.4% over 6 years (latest: -4.4%)
How much profit was generated on shareholders’ equity. Roughly 10%+ is often cited as solid for a U.S. company, though this varies a lot by industry and capital intensity.
09
Business modelSite analysis
Business Model Canvas
The whole company in nine blocks. Left side: how it delivers (partners, activities, resources, costs). Right side: who it serves and how it earns. Every entry comes from the company’s filings shown on this page.
08 · who helps
Key partners
- Eli Lilly (TuneLab)
07 · what it does
Key activities
Discovery and Safety Assessment
Discovery services- Safety and toxicology studies
Research Models and Services
Producing research models- Colony management at client sites
Manufacturing Solutions
Lot-release and quality-control testing
06 · what it draws on
Key resources
Discovery and Safety Assessment
Laboratories and scientists- Research models, including non-human primates
Research Models and Services
Breeding facilitiesManufacturing Solutions
Testing platforms
02 · why customers buy
Value propositions
- Early-stage drug development expertise across discovery, safety assessment, research models and quality testing.
04 · how it keeps them
Customer relationships
- Multi-study relationships with biopharma clients, shown in a backlog of about $1.9 billion for discovery and safety assessment.
03 · how it reaches them
Channels
- Direct sales force, supplemented by international distributors and agents; e-commerce for some products.
01 · who it serves
Customer segments
Discovery and Safety Assessment
Large pharma, mid-size and emerging biotechResearch Models and Services
Pharma, biotech, academia, governmentManufacturing Solutions
Drug manufacturers
09 · where money goes
Cost structure
FY2025, share of revenue ($4.02B)
- Selling, general & administrative18.5%
- Other operating costs (incl. cost of goods sold)80.9%
Operating profit left: 0.6% of revenue. Depreciation & amortization (inside the costs above): $403M. Capital spending: $219M.
Source: Form 10-K income statement and cash-flow statement (SEC XBRL).
05 · how money comes in
Revenue streams
Discovery and Safety Assessment
Study feesResearch Models and Services
Model sales and servicesManufacturing Solutions
Product and testing fees
Value propositions, channels and customer relationships: Form 10-K (FY2025)
Discovery and Safety Assessment (DSA)
Outsourced drug discovery and the non-clinical safety testing that regulators require for new drugs, vaccines, chemicals and devices.
01 what it draws on
Inputs & resources
- Laboratories and scientists
- Research models, including non-human primates
02 what it does
Activities
- Discovery services
- Safety and toxicology studies
- Bioanalysis
03 who it serves
Customers
- Large pharma, mid-size and emerging biotech
04 how money comes in
How it earns
- Study fees
Discovery and Safety Assessment (DSA): how it makes money
- 2025 revenue $2.40B (−2.0%), operating income $425M.
- The company raised its 2026 guidance partly on improving DSA demand.
Research Models and Services (RMS)
Production and sale of research models (over 140 stocks and strains of purpose-bred rodents) and related services such as insourcing solutions.
01 what it draws on
Inputs & resources
- Breeding facilities
02 what it does
Activities
- Producing research models
- Colony management at client sites
03 who it serves
Customers
- Pharma, biotech, academia, government
04 how money comes in
How it earns
- Model sales and services
Research Models and Services (RMS): how it makes money
- 2025 revenue $846M (+2.0%); operating income fell to $45M after a $102M intangible impairment.
Manufacturing Solutions
Microbial Solutions (rapid quality-control testing, such as Endosafe) and Biologics Solutions (testing of biologics).
01 what it draws on
Inputs & resources
- Testing platforms
02 what it does
Activities
- Lot-release and quality-control testing
03 who it serves
Customers
- Drug manufacturers
04 how money comes in
How it earns
- Product and testing fees
Manufacturing Solutions: how it makes money
- 2025 revenue $766M; operating loss of $184M, including a $165M goodwill impairment in Biologics Solutions.
Government & regulation around the business
Non-market factors from the company’s filings: what governments and regulators fund, buy, set, approve or restrict, and which part of the flow above each one touches.
Charles River is exposed to changes in trade, environmental and antitrust policy.
Trade & export rules
Tariffs and trade rules
Changes in trade policy, environmental regulation or antitrust enforcement could affect the business.
Constrains the businessTouches: Inputs & resourcesSource: Form 10-K (FY2025)
Revenue by segment (FY2025)
Unit: $M — bar length = revenue, (%) = share of total company revenue, margin = segment profit ÷ segment revenue × 100
DSA
2,402.9 (60%)profit 424.6 · margin 17.7%
RMS
846.1 (21%)profit 44.6 · margin 5.3%
Manufacturing
766.4 (19%)profit -184.3 · margin -24.0%
Source: Form 10-K (FY2025) — MD&A, segment results Profit is segment operating income; unallocated corporate costs were $259.7M.
10
Where it earnsSite analysis
Many U.S.-listed companies earn most of their revenue outside the U.S. — this breaks down revenue by country/region so it's clear where the business actually makes its money.
Largest market ()
U.S. — 53% of revenue
Revenue by country / region ()
Unit: — bar length = revenue, (%) = share of total company revenue
U.S.
2,141.8 (53%)Europe
1,102.7 (27%)Canada
501 (12%)Asia Pacific
205 (5%)Other
64.9 (2%)
Source: Form 10-K (FY2025) — revenue by geographic area By location of the selling entity. Other covers Brazil, Israel and Mauritius.
11
Contract structureSite analysisShow
Short-term or spot sales carry different earnings quality than long-term or auto-renewing contracts — this shows how the company actually contracts with its customers.
12
Alliances & capital tiesSite analysisShow
Equity stakes, joint ventures, and strategic partnerships disclosed across the 10-K, 8-Ks, and proxy statement.
Business partnership
Eli Lilly (TuneLab)
Charles River joined Lilly's TuneLab AI/ML platform, providing non-clinical testing expertise.
Source: Q2 2026 press release
13
Customers & suppliersSite analysis
Who the company sells to and buys from. Companies rarely name either, so named counterparties come only from the company's own filings and press releases; otherwise this lists the concentration figures the 10-K discloses.
Customers
Pharma and biotech companies, hospitals, academic institutions, government agencies and NGOs.
Named by the company
No client exceeded 4% of revenue.
Suppliers
Research model inputs, including non-human primates from audited and approved suppliers.
Named by the company
No supplier is named.
14
Competitors & peersSite analysis
Competitors the 10-K names, and the peer group the company itself chose in its proxy statement. Nothing here is this site's own pick.
The 10-K describes competitors including CROs, CDMOs, other service companies, universities and clients' internal departments, but does not name them.
Competitors named in the 10-K
Charles River's 10-K doesn't name competitors.
Peer group the company chose
2025 proxy peer group (37 companies), from the proxy statement. Peers are companies the board considers comparable — for example when setting executive pay — not necessarily direct competitors.
Used with survey data for a market composite benchmark. For 2026, Catalent is to be removed and Cooper Companies added.
- Abbott Laboratoriessite ↗
- Fortreasite ↗
- Myriad Geneticssite ↗
- Agilent Technologiessite ↗
- Gilead Sciencessite ↗
- Revvitysite ↗
- Amgensite ↗
- Hologicsite ↗
- Pfizersite ↗
- Avantorsite ↗
- ICON plcsite ↗
- Quest Diagnosticssite ↗
- Baxter Internationalsite ↗
- IDEXX Laboratoriessite ↗
- Regeneron Pharmaceuticalssite ↗
- Becton Dickinsonsite ↗
- Illuminasite ↗
- STERISsite ↗
- Bio-Rad Laboratoriessite ↗
- IQVIAsite ↗
- Teleflexsite ↗
- Biogensite ↗
- Jazz Pharmaceuticalssite ↗
- Thermo Fisher Scientificsite ↗
- Boston Scientificsite ↗
- Labcorpsite ↗
- Vertex Pharmaceuticalssite ↗
- Bristol-Myers Squibbsite ↗
- Medpacesite ↗
- Waterssite ↗
- Brukersite ↗
- Medtronicsite ↗
- West Pharmaceutical Servicessite ↗
- Catalentsite ↗
- Merck & Co.site ↗
- Eli Lillysite ↗
- Mettler-Toledosite ↗
Company names link to this site’s analysis where one exists; “site ↗” opens the company’s own website.
15
M&A historySite analysisShow
Companies acquired over the last five years, plus older large acquisitions that still anchor a current business — what each was bought to do, and what happened afterward. From the 10-K, 8-Ks, and the company's press releases.
Recent acquisitions are small and focused on supply and science.
Cash spent on acquisitions, FY2020–FY2025: $2.2B
2026-01
Assets of K.F. (Cambodia) Ltd.
Not stated
Cambodia-based provider of non-human primates for research.
- Stated purpose (company)
- Vertically integrate DSA's NHP supply.
Source: Form 10-K (FY2025) — Item 1
2026
PathoQuest SAS
Not stated
Next Generation Sequencing services.
- Stated purpose (company)
- Not stated.
Source: Q2 2026 press release
16
Six years of financialsFrom SEC data
Each chart's axis holds a single unit (never mixing dollars, %, and $/share). The table's per-period header links to the filing the numbers came from.
Revenue over time
Unit: $M
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-18
Profit over time (operating → net)
Unit: $M
- Operating income
- Pretax income
- Net income
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-18
Margins over time
Unit: %
- Operating margin
- Net margin
formulaoperating income ÷ revenue × 100
formulanet income attributable to the company ÷ revenue × 100
Cash flow over time
Unit: $M (below zero = cash went out)
- Operating CF
- Investing CF
- Free CF
formulacash flow from operations − capital expenditures
termsFree cash flow (FCF) · Cash flow from operations (operating CF) · Capital expenditures (capex)
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-18
Financial stability & capital efficiency
Unit: %
- Equity ratio
- ROE
formulatotal equity ÷ total assets × 100 (as reported in the 10-K)
termsStockholders’ equity · Total assets
formulanet income ÷ average equity (beginning + ending, ÷2) × 100 (as reported in the 10-K)
termsNet income (attributable to the company) · Stockholders’ equity
Earnings per share (EPS) and dividend per share
Unit: $
- EPS
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-18
| Line item | FY202010-K on EDGAR ↗ | FY202110-K on EDGAR ↗ | FY202210-K on EDGAR ↗ | FY202310-K on EDGAR ↗ | FY202410-K on EDGAR ↗ | FY202510-K on EDGAR ↗ |
|---|---|---|---|---|---|---|
| Income statement ($M) | ||||||
| Revenue | 2,924 | 3,540 | 3,976 | 4,129 | 4,050 | 4,015 |
| Operating income | 433 | 590 | 651 | 617 | 227 | 25 |
| Pretax income | 447 | 481 | 623 | 581 | 93 | -100 |
| Net income (attributable) | 364 | 391 | 486 | 475 | 22 | -144 |
| Revenue growthcalc(this year’s revenue − last year’s revenue) ÷ last year’s revenue × 100 | — | 21.1% | 12.3% | 3.9% | -1.9% | -0.9% |
| Operating margincalcoperating income ÷ revenue × 100 | 14.8% | 16.7% | 16.4% | 14.9% | 5.6% | 0.6% |
| Net margincalcnet income attributable to the company ÷ revenue × 100 | 12.5% | 11.0% | 12.2% | 11.5% | 0.5% | -3.6% |
| Balance sheet ($M) | ||||||
| Total assets | 5,491 | 7,024 | 7,603 | 8,195 | 7,528 | 7,135 |
| Total equity | 2,118 | 2,539 | 2,981 | 3,602 | 3,467 | 3,170 |
| Interest-bearing debtSum of short- and long-term borrowings, notes/bonds payable | 1,930 | 2,664 | 2,708 | 2,647 | 2,240 | 2,136 |
| Equity ratio | 38.5% | 36.1% | 39.1% | 43.9% | 46.0% | 44.4% |
| ROE | 17.2% | 16.8% | 17.6% | 14.4% | 0.6% | -4.4% |
| Cash flow ($M) | ||||||
| Operating CF | 547 | 761 | 620 | 684 | 735 | 738 |
| Investing CF | -602 | -1,438 | -608 | -563 | -245 | -209 |
| Financing CF | 47 | 673 | -42 | -86 | -551 | -537 |
| Free cash flowcalccash flow from operations − capital expenditures | 380 | 532 | 295 | 365 | 502 | 518 |
| Cash and equivalents | 228 | 241 | 234 | 277 | 195 | 214 |
| Per share & other | ||||||
| EPS ($) | 7.20 | 7.60 | 9.48 | 9.22 | 0.20 | -2.91 |
| BVPS ($) | 42.49 | 50.21 | 58.42 | 70.06 | 67.69 | 64.30 |
| P/E (x) | 35.0 | 48.6 | 23.0 | 25.6 | 930.8 | — |
| EV/EBITDA (x)calc(market cap + interest-bearing debt − cash and equivalents) ÷ (operating income + depreciation & amortization) | 21.3 | 24.6 | 14.2 | 15.6 | 19.6 | 27.9 |
| P/B (x)calcfiscal year-end closing price ÷ book value per share | 5.92 | 7.35 | 3.73 | 3.37 | 2.75 | 3.17 |
P/B and EV/EBITDA use each period’s period-end (fiscal year-end) figures, not the current share price. Figures without a "calc" tag are as reported in the Form 10-K (the consolidated financial statements and, for older years, earlier 10-Ks), pulled automatically from SEC EDGAR. Where a later filing restated a prior period, the restated figure is used.
Last 8 quarters
Three-month figures from 10-Q filings. Change is versus the same quarter a year earlier. Newest quarter on top.
| Quarter ended | Revenue | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|
| 2026-09-26 | $983M-2.2% | $203M+51.4% | $333M+512.0% | $6.86 |
| 2026-06-27 | $1B-2.7% | $120M+19.7% | −$1M-102.8% | $-0.03 |
| 2026-03-28 | $996M+1.2% | $120M+60.6% | −$15M-158.3% | $-0.30 |
| 2025-12-27 † | $994M-0.8% | −$283M | −$277M | — |
| 2025-09-27 | $1B | $134M | $54M | $1.10 |
| 2025-06-28 | $1.03B | $100M | $52M | $1.06 |
| 2025-03-29 | $984M | $75M | $25M | $0.50 |
| 2024-12-28 † | $1B | −$168M | −$214M | — |
† Fourth quarter = the 10-K’s annual figure minus the first three quarters; quarterly EPS isn’t derived this way because share counts change during the year.
17
Is ROIC above WACC?From SEC data
ROIC (the return on money invested in the business) above WACC (the cost of raising that money) means the company is creating value. WACC is an estimate, so its assumptions can be adjusted below.
ROIC (FY2025)
0.4%
formulaoperating income × (1 − tax rate) ÷ invested capital × 100 *invested capital = interest-bearing debt + total equity (average of beginning/ending)
e.g.$25M × (1 − 23%) ÷ $5,507M × 100 = 0.4%
termsOperating income · Effective tax rate · Invested capital · Interest-bearing debt · Total equity
WACC (this site’s estimate)
8.61%
formulacost of equity × equity weight + cost of debt × (1 − tax rate) × debt weight
e.g.Equity weight: $10.02B ÷ ($10.02B + $2.14B) = 82.4%
e.g.Debt weight: $2.14B ÷ ($10.02B + $2.14B) = 17.6%
e.g.WACC: 9.6% × 82.4% + 5.0% × (1 − 23%) × 17.6% = 8.61%
termsCost of equity · Equity weight (E/(D+E)) · Cost of debt · (1 − tax rate) · Debt weight (D/(D+E)) · Market capitalization
How firm is this? With the equity risk premium ±1 point and beta ±0.2, WACC runs 7.2%–10.4% and ROIC − WACC runs −10.0 to −6.8 points. The sign holds across this range. This describes the latest year and does not predict future value creation.
WACC 8.61% is this site’s estimate under the assumptions below (not a figure the company has published)
- Risk-free rate
- 4.95% (10-year Treasury, 2026-11-03)
- β
- 0.85 (price-derived adjusted beta, but correlation with the market is low (R² 0.05), so reliability is limited)
- Equity risk premium
- 5.5%
- Cost of equity
- 9.63%
- Cost of debt
- 5.01%
- Tax rate
- 23% (effective rate, FY2022–FY2024)
- Capital structure (equity : debt)
- 82% : 18%
ROIC over time, vs. WACC
Unit: % — bars = each period's ROIC, horizontal line = latest WACC. Bars above the line are green, below are red
- ROIC (above WACC)
- ROIC (below WACC)
- WACC 8.61%
formulaoperating income × (1 − tax rate) ÷ invested capital × 100 *invested capital = interest-bearing debt + total equity (average of beginning/ending)
termsOperating income · Effective tax rate · Invested capital · Interest-bearing debt · Total equity
formulacost of equity × equity weight + cost of debt × (1 − tax rate) × debt weight
termsCost of equity · Equity weight (E/(D+E)) · Cost of debt · (1 − tax rate) · Debt weight (D/(D+E)) · Market capitalization
Try different WACC assumptions
β and the equity risk premium are estimates with a real range of plausible values — move the sliders to check whether ROIC > WACC still holds. The risk-free rate starts at the 10-year Treasury yield on 2026-11-03 (U.S. Treasury).
Initial β: 0.85 (price-derived adjusted beta. Raw β 0.78, R² 0.05, 130 weeks)
formula0.67 × β + 0.33 (β = the slope of weekly stock returns regressed on weekly market returns)
e.g.0.67 × 0.775 + 0.33 = 0.850
termsβ (beta)
Period 2024-05-10–2026-11-04, using S&P 500 ETF (SPY) as the market proxy. Source: Yahoo Finance price history.
formularisk-free rate + β × equity risk premium
e.g.5.0% + 0.85 × 5.5% = 9.6%
termsCAPM · Risk-free rate · β (beta) · Equity risk premium (market risk premium)
formulafiscal year-end closing price × shares outstanding (= market cap)
formulainterest expense ÷ interest-bearing debt × 100 (clamped to 0–10%; falls back to the risk-free rate if there’s no debt)
18
What the price implies (DCF)From SEC data
A company's value can be written as its free cash flow divided by (cost of capital − perpetual growth). Working that backwards from the market's valuation shows how much growth the share price assumed — compared here with the company's actual past growth.
Growth the price implies (price on 2026-11-04)
5.8%
Perpetual FCF growth: g = r − FCF ÷ EV = 8.6% − 2.8%
Past FCF growth (FY2020–FY2025)
+6.4%
Compound annual rate, 5 years
Past revenue growth (FY2020–FY2025)
+6.5%
Compound annual rate, 5 years
Inputs (FY2025): free cash flow $518M (operating CF − capex); enterprise value $18.66B = market cap $16.73B (latest close, 2026-11-04) + debt $2.14B − cash and short-term investments $214M; r = WACC of 8.6% using this page’s default assumptions (β 0.85, risk-free 5.0%, market premium 5.5%).
Three WACC scenarios
The same calculation under cautious, base and optimistic cost-of-capital assumptions (risk-free rate fixed at the 10-year Treasury yield). Pick one to load it into the sliders below.
Try your own assumptions
V = FCF ÷ (r − g). It starts at the implied growth rate, where the theoretical value equals today’s enterprise value.
Theoretical enterprise value
$18.52B
FCF $518M ÷ (8.6% − 5.8%)
Theoretical ÷ actual enterprise value
0.99x
Below 1x: these assumptions value the business below the market did
How sensitive the answer is
Theoretical ÷ actual enterprise value for each combination of r and g.
| g \ r | 6.6% | 7.6% | 8.6% | 9.6% | 10.6% |
|---|---|---|---|---|---|
| 0% | 0.42x | 0.37x | 0.32x | 0.29x | 0.26x |
| 2% | 0.60x | 0.50x | 0.42x | 0.37x | 0.32x |
| 4% | 1.07x | 0.77x | 0.60x | 0.50x | 0.42x |
| 6% | 4.63x | 1.74x | 1.07x | 0.77x | 0.60x |
| 8% | — | — | 4.63x | 1.74x | 1.07x |
A simplified model for seeing what the market price assumes, not a forecast or a target price. It treats free cash flow as growing at one constant rate forever; the result swings widely with small changes in r and g, and is undefined when g reaches r. Free cash flow here is operating cash flow minus capex, which is after interest — a full DCF of enterprise value would use cash flow before interest. Market cap uses the latest close (2026-11-04) × shares at fiscal year-end; free cash flow and WACC inputs are from the latest fiscal year.
19
Earnings qualityFrom SEC dataShow
The same reported profit can mean different things depending on whether it's backed by cash, driven by the core business, or the result of a one-off item. Four checks below.
- ✓
Operating CF ÷ net income: averages 7.85x
Profit is backed by cash coming in.
- ✓
Accrual ratio (latest): -12.0%
A small share of profit rests on accounting estimates.
- ✓
Days sales outstanding: 77 → 65 days
No major slowdown in collecting on sales.
Operating CF vs. net income
Unit: $M — operating CF above net income means profit is backed by cash
- Operating CF
- Net income
formulacash flow from operations ÷ net income attributable to the company
termsCash flow from operations (operating CF) · Net income (attributable to the company)
formula(net income − operating CF) ÷ average total assets × 100
termsNet income (attributable to the company) · Cash flow from operations (operating CF) · Total assets
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-18
Profit bridge (FY2025)
Unit: $M — what moved profit from operating income to net income
- Profit (each stage)
- Pushed profit up
- Pushed profit down
formulaoperating income ÷ income before income taxes × 100
termsOperating income · Income before income taxes (pretax income)
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-18
Receivables & inventory days
Unit: days — days grow when receivables or inventory build up faster than sales
- Days sales outstanding
formulaaverage receivables (opening + closing ÷ 2) ÷ revenue × 365
formulaaverage inventory (opening + closing ÷ 2) ÷ cost of revenue × 365
termsInventory · Cost of revenue (COGS)
Worked examples (latest period)
formulacash flow from operations ÷ net income attributable to the company
termsCash flow from operations (operating CF) · Net income (attributable to the company)
formulaoperating income ÷ income before income taxes × 100
termsOperating income · Income before income taxes (pretax income)
formulaaverage receivables (opening + closing ÷ 2) ÷ revenue × 365
e.g.($721M + $709M) ÷ 2 ÷ $4,015M × 365 = 65 days
formulaaverage inventory (opening + closing ÷ 2) ÷ cost of revenue × 365
termsInventory · Cost of revenue (COGS)
20
Who holds the sharesFrom SEC dataShow
How much of the stock large institutional investors report owning on SEC Form 13F, how much the directors and executive officers hold (and how much of the vote they control), and roughly how much is left for individual investors. Shown next to beta so the holder mix can be read alongside how much the stock swings.
Institutions, insiders and everyone else, 13F holdings as of 2026-06-30
“Everyone else” is what remains after shares reported on Form 13F and shares held by directors and executive officers: mostly individual investors, plus non-insider families or foundations and smaller or foreign institutions. The figures have different dates and 13F reports count some shares twice — read it as an approximate split.
- Held by 13F filers
- 100%+
- Directors & officers (shares)
- 1.3%
- Everyone else (est.)
- ≈0%
- Directors & officers (voting power)
- 1.3%
- Institutional-ownership rank
- 2 of 416
- Beta (adjusted)
- 0.85
Reported total 119.1%
individuals and other non-13F holders
no separate voting figure; shown as shares
1 = most institutional; 0% of covered companies have more
above 1 = swings more than the market
- 56.8M shares reported by 569 13F filers ÷ 47.7M shares outstanding on 2026-07-25. Option positions are excluded.
- The 13F total exceeds shares outstanding because some shares are reported twice — for example shares lent to short sellers and then bought by another manager, or holdings that overlapping managers both report.
- Directors and executive officers as a group, from the proxy statement’s beneficial-ownership table; includes shares they can acquire within 60 days.
- A large “everyone else” share can still reflect a family, trust or foundation stake held outside the board; check the proxy statement’s 5% holders.
Sources: SEC Form 13F data set (holdings as of 2026-06-30) · Form DEF 14A filed 2026-03-31 (beneficial ownership table) · Form 10-Q cover page (shares outstanding as of 2026-07-25)
21
Strengths & weaknessesSite analysis
Strengths
1. Broad client base
No client exceeded 4% of revenue in 2025.
Evidence: Form 10-K (FY2025) Item 1
2. Cash flow
Operating cash flow was about $738M in 2025 despite the GAAP loss.
Evidence: SEC EDGAR XBRL
3. Improving demand
Q2 2026 organic growth of 0.1% was the highest since Q3 2023; the company raised its 2026 guidance.
Evidence: Q2 2026 press release
Weaknesses
1. Impairments and losses
Net income fell from $475M (2023) to $22M (2024) and a loss of $144M (2025).
Evidence: SEC EDGAR XBRL
2. Revenue decline
Revenue fell from $4.13B (2023) to $4.02B (2025).
Evidence: Form 10-K (FY2025)
22
What draws investors to itSite analysis
Why the stock can look attractive to investors — each point paired with what has to hold for it to stay true, and the opposing view. This is this site's analysis, not a recommendation to buy or sell.
P/E (FY2025)
—
Price at fiscal year-end ÷ diluted EPS
Dividend yield (FY2025)
—
Dividends per share ÷ fiscal year-end price
Payout ratio (FY2025)
—
Dividends per share ÷ diluted EPS
FCF yield (FY2025)
5.2%
(Operating CF − capex) ÷ market cap
1. Recovery potential
Organic growth turned positive in Q2 2026 and guidance was raised.
- What has to hold
- Biopharma R&D demand keeps improving.
- The other side
- GAAP results remain weak.
Evidence: Q2 2026 press release
2. Buybacks
Charles River repurchased $350M of stock in 2025 and $100M in Q2 2026.
- What has to hold
- Cash flow holds.
- The other side
- No dividend.
Evidence: Form 10-K (FY2025); Q2 2026 press release
Charles River pays no dividend. The fiscal year ends on the last Saturday of December.
23
ResilienceSite analysisShow
How well the company could absorb a bad year: its financial buffer, how its revenue and profit held up in the worst year on record, and what the 10-K says about the business's exposure to shocks. Figures and filing statements only — no overall rating.
1. Financial buffer (FY2025)
Cash & short-term investments ÷ debt due within a year
100x+
$214M vs. $166,000
Interest coverage (operating income ÷ interest expense)
0.2x
$25M vs. $107M
Free cash flow ÷ dividends paid
—
2. Worst year in the record, and the recovery
| Figure | Worst year-over-year change | Back to the prior level? |
|---|---|---|
| Revenue | -1.9% in FY2024 ($4.13B → $4.05B) | Not yet, as of FY2025 |
| Operating income | -88.9% in FY2025 ($227M → $25M) | Not yet, as of FY2025 |
Covers only the 6 fiscal years on record (FY2020–FY2025), which may not include a full recession — the worst year here isn’t necessarily how the company would fare in a severe downturn.
3. Business resilience (from the 10-K)
Diversified clients
No client exceeded 8% of any segment's revenue.
Source: Form 10-K (FY2025), Item 1
Cost actions
The company reduced headcount by about 2% and is consolidating sites.
Source: Form 10-K (FY2025), Human Capital
24
Legal & regulatory mattersSite analysisShow
Lawsuits, government investigations, enforcement actions and settlements the company discloses — where each stands, what is at stake, and what comes next. From the 10-K's Legal Proceedings and contingencies note, the latest 10-Q, and 8-Ks.
Charles River faces a revived securities class action, with related derivative suits, over its disclosures on importing non-human primates.
1 open matter
Non-human primate import securities class action
PendingClass actionPutative class of purchasers, May 2020 – February 2023 (D. Mass.)
Alleges misleading disclosures about non-human primate import practices. Dismissed in July 2024, then partly revived by the First Circuit on August 15, 2025. In October 2025 the plaintiffs moved to substitute Oklahoma Firefighters as lead plaintiff.
- Next step
- Two derivative suits in D. Del. are stayed pending the class action.
Source: Form 10-Q (quarter ended 2026-06-27) — Legal Proceedings
Company statement: Charles River believes no other pending matters could have a material impact.
Based on Form 10-Q (quarter ended 2026-06-27) — Legal Proceedings, reviewed 2026-10-18. Routine ordinary-course claims are not listed. “Major” is this site’s judgment of which matters could materially affect results.
25
Risks (including geopolitical)Site analysis
Starting from the 10-K's Risk Factors section, organized by category — geopolitical, currency, raw materials, regulatory, disaster, and more — with impact and likelihood assessed by this site.
Risk map
Vertical = impact on results, horizontal = likelihood. Upper right = most severe. Numbers match the list below (placement is this site’s own assessment).
Likelihood →
"Company disclosure" vs. "this site’s assessment"
The description and mitigation for each risk are this site’s summary of the 10-K’s "Risk Factors" section. Impact and likelihood are this site’s own assessment, not the company’s — where the company discloses its own likelihood assessment, that is noted in the summary.
Impact is judged from how large the affected business is relative to total revenue/profit, and from the risk’s track record of moving results in the past. Likelihood is judged from the filing’s wording and the current business environment (already occurring, or recurring). See the rating criteria.
- 1Supply chain
Non-human primate supply
- Company disclosure (summarized from the 10-K)
- Charles River depends on NHP availability and on procedures to ensure imported NHPs are purpose-bred. In January 2026 it bought assets of K.F. (Cambodia), an NHP supplier.
- Company’s stated mitigation
- Diversifying the NHP supply chain.
- This site’s assessment
- Impact High / Likelihood Med
- 2Demand & macro
Biopharma spending
- Company disclosure (summarized from the 10-K)
- Client budget cuts and study cancellations reduce demand.
- Company’s stated mitigation
- Restructuring and cost actions.
- This site’s assessment
- Impact Med / Likelihood High
- 3Competition & technology shift
Competition and alternatives
- Company disclosure (summarized from the 10-K)
- Charles River competes with CROs, CDMOs, universities and clients' in-house departments; competitors may develop superior technologies.
- Company’s stated mitigation
- Investment in in vitro and bioanalysis capabilities.
- This site’s assessment
- Impact Med / Likelihood Med
- 4Law & regulation
Litigation
- Company disclosure (summarized from the 10-K)
- Securities class action and derivative suits relate to NHP sourcing. In November 2025 the SEC staff said it does not intend to recommend enforcement action.
- Company’s stated mitigation
- SEC investigation closed without enforcement recommendation.
- This site’s assessment
- Impact Med / Likelihood Med
26
What changed in the risk factorsFrom SEC data
Paragraphs in the latest 10-K's Risk Factors that have little overlap with the year before, and paragraphs that were dropped.
New or substantially reworded (8)
• Our review of potential strategic alternatives may not result in an executed or consummated transaction or other strategic alternative, and the process of reviewing strategic alternatives or the outcome could adversely affect our business.
We leverage software and hardware solutions from technology and services providers, including software-as-a-service and public cloud infrastructure, who have been subject to cybersecurity incidents in the past and may have incidents or breaches in the future. As of the date of this filing, to our knowledge, no prior cybersecurity incident or breach at a third party has had a material impact on our business. However, future incidents or breaches could cause us to suffer significant harm.
Uncertainties with respect to the development, deployment, and use of artificial intelligence present new risks and challenges and could adversely affect our business and reputation.
We, along with many businesses in the biopharmaceutical industry, are adopting and exploring the use of artificial intelligence (AI) in our business, and as an emerging and rapidly evolving technology, our use of AI introduces potential opportunities but also presents risks that could adversely affect our operations, information security and reputation. For example, algorithms may be flawed; data sets may be insufficient, of poor quality, or contain biased information; and inappropriate or controversial data practices by data scientists, engineers, and end-users could impair results. If the analyses that artificial intelligence-based applications assist in producing are deficient or inaccurate, we could be subjected to competitive harm, potential legal liability and brand or reputational harm. Use of AI-based software may also lead to cybersecurity risks or the release of confidential…
Our review of potential strategic alternatives may not result in an executed or consummated transaction or other strategic alternative, and the process of reviewing strategic alternatives or the outcome could adversely affect our business.
On May 6, 2025, in connection with a Cooperation Agreement entered into with a large shareholder of the Company, we agreed, among other things, to have the Strategic Planning and Capital Allocation Committee of our Board of Directors oversee and direct a comprehensive strategic review and evaluation of the Company’s business and prospects, including an examination of various alternatives to enhance long-term stockholder value. On November 5, 2025, the Company announced that, as part of our Board of Directors’ comprehensive strategic review of our business and growth prospects, we will focus on strategic initiatives to strengthen our leading scientific portfolio within our core markets through strategic acquisitions, partnerships, and internal investments; divest certain non-core assets; maximize our financial performance, including by implementing additional initiatives aimed at driving…
The process of reviewing potential strategic and operational alternatives is time consuming and costly and may divert management’s attention. Read more
It may also be disruptive to our business operations and long-term planning, which may cause concern to our current or potential investors, customers, employees, strategic partners, vendors and other stakeholders and may have a material impact on our operating results or result in increased volatility in our stock price.
Any potential transaction or other strategic alternative, including, without limitation the acquisitions of the assets of K.F. Read more
(Cambodia) Ltd. and Pathoquest SAS, would be dependent on a number of factors that may be beyond our control, including, among other things, market conditions, industry trends, regulatory approvals, and the availability of financing for a potential transaction on favorable terms. There can be no assurance that any potential transaction or other strategic alternative will be successfully implemented, achieve the intended benefits or provide greater value to our stockholders than that reflected in the current price of our common stock. Until the review process is concluded, perceived uncertainties related to our future may result in the loss of potential business opportunities, volatility in the market price of our common stock and difficulty attracting and…
7 more paragraphs differ; the filings below have the full text.
Matched automatically, quoted as filed, and may include rewording of an existing risk. Compares Item 1A of the 10-K filed Feb 18, 2026 ↗ with the 10-K filed Feb 19, 2025 ↗.
27
What to watch going forwardSite analysis
- DSA demand and bookings.
- NHP supply.
- Progress on the Create the Future savings program (over $300M of cumulative savings expected for 2027–2030).
- Portfolio divestitures.
- Buybacks ($1.0B authorization from October 2025).
28
Source documentsShow
This page's financial figures come from the Form 10-Ks listed below. Check the original filings for full detail.
Last updated
Analysis last edited: October 14, 2026 · Financial data fetched: October 17, 2026 10:07 (SEC EDGAR) · Source 10-K filed: February 18, 2026
Built on10-K FY2025 · filed 2026-02-18
Next update expectedAfter FY2026’s 10-K is filed (roughly 60–90 days after fiscal year end (sooner for larger filers)), financials and analysis will be refreshed.
This page is this site’s own analysis based on public information, and does not represent Charles River Laboratories’s views. It is not a recommendation to buy or sell any security, and this site does not guarantee the accuracy of any figure or statement here. Always verify against the original source documents before making an investment decision.